Peptide Cancer Vaccine Market – Global Industry Insights, Trends, Opportunity Analysis, 2021-2027 the new research from Coherent Market Insights has announced report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The Peptide Cancer Vaccine Market offers a summary of product specification, production analysis, technology, product type, considering key features such as gross margin, revenue & cost. Peptide Cancer Vaccine Market report provides key statistics on the Market status of the Peptide Cancer Vaccine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1634
The Peptide Cancer Vaccine market size is projected to reach USD 1329.2 million by 2027, from USD 553 million in 2020, at a CAGR of 19.6% during 2021-2027
Peptide cancer vaccines support for eliciting and expanding T-cells that are tumor-specific capable to control or eradicate tumor. This vaccine includes a single or more short/long sequences of amino acid as tumor antigens, coupled with the vaccine adjuvant. Recently, clinical trial results that was performed with the use of peptide cancer vaccine, exhibited negative end-results. Hence, researchers from peptide vaccines have considered it as an outdated therapy, declaring it as feasible no longer for treatment of cancer. However, rising progress to understand critical roles of the immune adjuvants, vaccine administration modes, and dynamics of T-cell has resulted in re-emergence of the approach to treat malignant disorders.
Moreover, benefits involved in usage and preparation of peptide vaccines are easy for synthesizing, easy to prepare, cost-effective, and its applications within clinical practices, flexibility to change antigen, along with low risk anaphylaxis, which is antigen-induced is expected to drive the global peptide cancer vaccine market growth in the near future. Hence, due to such benefits, manufacturers are focused on research, for developing vaccines of peptide cancer. For instance, Boston Biomedical, Inc., engaged in next-generation cancer therapeutics, in April 2018, began dosing of its first patient from each of the two clinical trials for evaluating the results of its efficacy through using DSP-7888 – the investigational vaccine of cancer peptide.
Global Peptide Cancer Vaccine Market Dynamics
Factors that are expected to drive growth of the global peptide cancer vaccine market over the forecast period are, rising incidence of cancer along with failure of traditional methods to effectively treat the disease, leading to rising demand for novel therapies that are immunotherapy-based including peptide vaccine. In 2016, as per the National Cancer Institute, over 16.8 Mn new cancer cases were diagnosed, where over 595,690 people lost lives due to disease in the U.S. Number of individuals with cancer are expected to increase to 19 Mn by 2024. Moreover, the World Health Organization (WHO) stated that in 2012, around 14 Mn cancer cases and 8.2 Mn deaths due to the disease. From these, prevalent cases included lung, colorectal, cervical, breast cancer, and prostate, which has significantly increased the peptide vaccine demands, in turn expected to fuel growth of the global peptide cancer vaccine market over the forecast period.
Moreover, for catering the increasing vaccine demands, manufacturers are involved in acquisitions and mergers and new launches of product in the global peptide cancer vaccine market. For instance, Merck & Co., in May 2018, invested over US$ 125 Million in the Moderna Therapeutics. The expansion comprised partnering on Moderna’s cancer vaccine mRNA KRAS, mRNA-5671, along with other cancer vaccines of shared antigen mRNA. The vaccine consists the mRNA for 4 most frequently detected KRAS mutation, which as per the Moderna would cover majority of mutations that occur within non-small-cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer. Moderna, in November 2017, launched the KEYNOTE-603 Phase I study of the mRNA-4157, a personalized cancer vaccine that is mRNA-based developing with the Merck & Co., from an mRNA partnership worth US$ 100 Mn+.
Furthermore, TapImmune Inc., a immune-oncology firm in clinical-stage with continuing clinical studies in ovarian and breast cancer, in November 2017, declared that company has registered a final patient within randomized clinical study in Phase 2 for its new vaccine candidate of T-cell -TPIV200 to treat triple-negative breast cancer (TNBC). Further clinical studies for vaccines of peptide cancer are expected to drive the global peptide cancer vaccine market growth over the forecast period.
Global Peptide Cancer Vaccine Market – Regional Insights
North America accounted for the largest share in the global peptide cancer vaccine market, preceding Europe in 2016. It is due to presence of high numbers of key biotech and pharmaceutical players in this region including Pfizer, Inc., Merck, Novartis, GlaxoSmithKline, Roche, and others. Furthermore, increasing incidence of cancer is expected to drive growth of the global peptide cancer vaccine market over the forecast period. As per the National Cancer Institute, in 2016, over 16.8 Mn new cancer cases in the U.S. were diagnosed, with around 595,690 deaths owing the disease. Number of individuals having cancer is expected to surge to 19 Mn by 2024.
Moreover, several biotechnological and pharmaceutical companies are focused on expansion in Asia Pacific along with conducting activities of R&D to provide better access to the patients in clinical trials along with offering low-cost efficiencies in operation. Rising government investments in R&D is also expected to drive the global peptide cancer vaccine market growth in Asia Pacific.
Global Peptide Cancer Vaccine Market – Taxonomy:
Based on Pipeline Phase:
Based on Application:
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Prostate Cancer
- Gastric Cancer
- Breast Cancer
Based on Region:
- North America
- Latin America
- Asia Pacific
- Middle East
Buy This Complete Business Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/1634
Major Players Are: TapImmune, Merck, BrightPath Biotherapeutics, Sellas, BioLife Science, Boston Biomedical, VAXON Biotech, Lytix Biopharma, ISA Pharmaceuticals, Generex Biotechnology, OncoTherapy Science, Enzo Life Science, Antigen Express, Immatics Biotechnologies, Immatics, Immune Design, Immunomedics, Galena Biopharma, Generex Biotechnology Corporation, and Ultimovacs.
Main points in Peptide Cancer Vaccine Market Report Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Peptide Cancer Vaccine Market Size Analysis from 2021 to 2027
11.6 COVID-19 Outbreak: Peptide Cancer Vaccine Industry Impact
Chapter 2 Peptide Cancer Vaccine Competition by Types, Applications, and Top Regions and Countries
2.1 Peptide Cancer Vaccine (Volume and Value) by Type
2.3 Peptide Cancer Vaccine (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Peptide Cancer Vaccine Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Peptide Cancer Vaccine Market Analysis
Chapter 6 East Asia Peptide Cancer Vaccine Market Analysis
Chapter 7 Europe Peptide Cancer Vaccine Market Analysis
Chapter 8 South Asia Peptide Cancer Vaccine Market Analysis
Chapter 9 Southeast Asia Peptide Cancer Vaccine Market Analysis
Chapter 10 Middle East Peptide Cancer Vaccine Market Analysis
Chapter 11 Africa Peptide Cancer Vaccine Market Analysis
Chapter 12 Oceania Peptide Cancer Vaccine Market Analysis
Chapter 13 South America Peptide Cancer Vaccine Market Analysis
Chapter 14 Company Profiles and Key Figures in Peptide Cancer Vaccine Business
Chapter 15 Peptide Cancer Vaccine Market Forecast (2021-2027)
Chapter 16 Conclusions
Major Point Answered in Peptide Cancer Vaccine Market Research Study are: –
• What will the market growth rate, Overview and Analysis by Type of Peptide Cancer Vaccine market in 2027?
• What are the key factors driving, Analysis by Applications and Countries Peptide Cancer Vaccine market?
• What are Dynamics, This Overview Includes Analysis of Scope, and price analysis of top Manufacturers Profiles of Peptide Cancer Vaccine market?
• Who are Opportunities, Risk and Driving Force of Peptide Cancer Vaccine market? Knows Upstream Raw Materials Sourcing and Downstream Buyers
• Who are the key vendors in Peptide Cancer Vaccine market space? Business Overview by Type, Applications, Gross Margin and Market Share
• What are the Peptide Cancer Vaccine market opportunities and threats faced by the vendors in the market?
Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1634
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027